A GLP‐1R/Y<sub>1</sub> receptor/Y<sub>2</sub> receptor triple agonist decreases fentanyl‐evoked dopamine release in the nucleus accumbens and attenuates fentanyl taking and seeking in rats
Together, these findings support the continued development of GLP-1R/Y<sub>1</sub> receptor/Y<sub>2</sub> receptor triple agonists as a novel class of pharmacotherapies for treating OUD.
Authors
- Robert P. Doyle (ORCID: https://orcid.org/0000-0001-6786-5656)
- Kylie S. Chichura
- Heath D. Schmidt (ORCID: https://orcid.org/0000-0002-0646-5605)
- Matthew R. Hayes (ORCID: https://orcid.org/0000-0001-9782-6551)
- Antonia Caffrey (ORCID: https://orcid.org/0009-0000-5604-8239)
- Enzo Lavecchia (ORCID: https://orcid.org/0009-0007-4670-3499)
Institutions
- SUNY Upstate Medical University (US)
- Syracuse University (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2025-06-02
- DOI
- https://doi.org/10.1111/bph.70096
- Primary Topic
- Neuropeptides and Animal Physiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- University of Pennsylvania
- National Institutes of Health